|
| 36987929 | Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation. | Eur J Heart Fail | 2023 |
| 36303404 | Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. | Eur Heart J | 2023 |
| 35983667 | Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration? | European Heart Journal | 2023 |
| 35980763 | A polygenic risk score predicts atrial fibrillation in cardiovascular disease. | Eur Heart J | 2023 |
| 37606894 | Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review. | | 2023 |
| 37606673 | Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. | JAMA | 2023 |
| 37585218 | Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review. | | 2023 |
| 37345760 | Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT. | J Am Heart Assoc | 2023 |
| 36779348 | Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. | Circulation | 2023 |
| 37344040 | Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. | J Am Coll Cardiol | 2023 |
| 37211048 | Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trial. | Int J Cardiol | 2023 |
| 36763180 | Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial. | | 2023 |
| 37068132 | Response by O'Donoghue et al to Letter Regarding Article, "Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease". | Circulation | 2023 |
| 37042255 | Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF. | Circulation | 2023 |
| 37100536 | Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure Phenotypes. | | 2023 |
| 37038327 | Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. | Eur Heart J | 2023 |
| 35086664 | Reply: Analyzing IMPROVE-IT Beyond LDL Cholesterol. | J Am Coll Cardiol | 2022 |
| 35593128 | Relationship of diabetes, heart failure, and N-terminal pro-B-type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation. | ESC heart failure | 2022 |
| 35583875 | Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. | JAMA Cardiology | 2022 |
| 36031810 | Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. | Circulation | 2022 |
| 35760720 | Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. | J Clin Lipidol | 2022 |
| 36017608 | Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial. | Europace | 2022 |
| 36007987 | Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial. | J Am Coll Cardiol | 2022 |
| 35695614 | Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction. | Current Opinion in Lipidology | 2022 |
| 35367005 | Acute coronary syndromes. | Lancet, The | 2022 |
| 36202288 | The non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with high-normal renal function - A systematic review. | Vascular Pharmacology | 2022 |
| 35483753 | Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction. | J Am Coll Cardiol | 2022 |
| 35475346 | Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239Â 234 Patients During 2005 to 2018 in the United States. | Journal of the American Heart Association | 2022 |
| 36260325 | Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT. | JAMA Cardiol | 2022 |
| 35404972 | No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. | PLoS One | 2022 |
| 34990581 | Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. | American Heart Journal | 2022 |
| 34985309 | Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. | Circulation | 2022 |
| 35261279 | Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE-IT PCI. | J Am Heart Assoc | 2022 |
| 35218519 | Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. | Advances in Therapy | 2022 |
| 35209731 | Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention. | Circ Cardiovasc Interv | 2022 |
| 34962979 | Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. | European Heart Journal - Cardiovascular Pharmacotherapy | 2022 |
| 35185404 | Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation. | European Heart Journal, Supplement | 2022 |
| 34773460 | Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. | JAMA Cardiol | 2022 |
| 35112882 | Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT. | J Am Heart Assoc | 2022 |
| 34537830 | Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial. | Eur Heart J | 2021 |
| 36713994 | Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data. | Eur Heart J Digit Health | 2021 |
| 33493453 | Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 study. | Am Heart J | 2021 |
| 34298555 | LDL-cholesterol lowering with evolocumab, and outcomes according to age and sex in patients in the FOURIER Trial. | Eur J Prev Cardiol | 2021 |
| 33587659 | Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. | Circulation | 2021 |
| 33587654 | Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials. | Circulation | 2021 |
| 34279993 | Combining High-Sensitivity Troponin With the American Heart Association/American College of Cardiology Cholesterol Guidelines to Guide Evolocumab Therapy. | Circulation | 2021 |
| 34167651 | Reply: Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration? | Journal of the American College of Cardiology | 2021 |
| 33625716 | Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance". | Drug Safety | 2021 |
| 34160553 | Myocardial Infarction and Evolocumab-Reply. | JAMA Cardiol | 2021 |
| 33663737 | Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. | Journal of the American College of Cardiology | 2021 |